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PPN15
MULTIPLE PAIN RELIEF ASSESSMENT IN 
WOMEN UNDERGOING NATURAL VERSUS 
EPIDURAL DELIVERY WITH ROPIVACAIN
OR BUPIVACAIN
Szende A1, Kincses ZS2, Zimanyi M3, Kadar Z4, Zorenyi G1
1AstraZeneca, Torokbalint, Hungary; 2Semmelweis University, 
Budapest, Hungary; 3Albert Szentgyorgyi Medical University, 
Szeged, Hungary, 4Diosgyor City Hospital, Diosgyor, Hungary
OBJECTIVES: To compare level of pain and pain relief
by using different outcome measurement techniques in
women undergoing natural and epidural delivery. To
identify the relationship between categorical self-assess-
ment and continuos VAS measures in painless delivery.
METHODS: 300 women at 10 centres in Hungary un-
dergoing natural, epidural (ropivacain), or epidural
(bupivacain) delivery were involved in this non-random-
ized, open study. To avoid selection bias, patients were
recruited consecutively and natural delivery patients
came from centres where epidural delivery was not of-
fered. Pain was measured by 10cm visual analogue scale
and by categorical self-assessment questions before pain
relief, at 15, 30 minutes, and then hourly afterwards. Pa-
tient’s preferred choice for possible future delivery was
also recorded. ANOVA method was used to test statisti-
cal significance. RESULTS: Initial average pain level
measured by VAS was 6.9 cm. Initial pain level did not
differ across groups. Changes in pain between the two
epidural groups were not statistically significant. De-
crease in VAS scores was 3.3, 5.3, and 5.1 cm at 15, 30,
and 60 minutes after drug administration, respectively.
Changes assessed by patients as some, good, and excel-
lent pain relief was associated with an average change of
1.80; 3.75; and 5.67 cm in VAS, respectively. Good or
excellent pain relief was experienced in 91% of epidural
patients. All of the epidural group and 70% of the natu-
ral group would choose painless delivery at a possible fu-
ture occasion. Most reasons related to decreased pain,
less tiredness, better compliance with doctors, and more
attention to the baby. P values were less than 0.05. CON-
CLUSIONS: Large decrease in pain level can be achieved
in epidural groups at small additional costs and this is re-
flected in patients’ preferences. Validation of the VAS
method in painless delivery by assessment of importance
of change can be highly useful in future VAS studies.
PPN16
ECONOMIC BURDEN AND LOSS IN QUALITY OF 
LIFE DUE TO LOW BACK PAIN
Szende A1, Lovas K2, Szebenyi B3, Bàlint G3, Héjj G3
1AstraZeneca, Torokbalint, Hungary; 2Semmelweis University, 
Budapest, Hungary; 3National Institute of Rheumatology and 
Physiotherapy, Budapest, Hungary
OBJECTIVES: Low back pain is a common health prob-
lem in the population but its impact on quality of life and
societal costs is not well identified yet. The objective of
this study was to measure quality of life and costs related
to LBP and to understand the relationship among these
measurements. METHODS: 87 LBP patients (56 fe-
males) of mean age of 55 were recruited within a mus-
culoskeletal study in both primary care and rheumatol-
ogy outpatient settings in Hungary in 2000. Patients
filled in the generic EQ-5D quality of life and the disease
specific Oswestry questionnaires and reported health care
utilization. Mean quality of life and utilization values
were analysed and correlation coefficients between dif-
ferent measurements were reported. RESULTS: Average
EQ-5Dindex, EQ-5Dvas, and Oswestry score were 0.48;
0.52; 40, respectively. QoL did not differ significantly
across sub-diagnoses (i.e. discopathia, lumboischialgia,
osteoporosis, spondylitis ankylopoetica, and other) groups
of LBP. Average annual number of physiotherapy and
spa/pool treatment occasions was 8.9 and 2, respectively.
Average number of GP and specialist visits were 7.5 and
4. Patients spent a mean of 2.9 days in hospital and they
spent 12.7 days in bed due to LBP. Active workers re-
ported 16.6 days spent on sick leave. Statistically signifi-
cant correlation was observed between EQ-5Dindex and
EQ-5Dvas; EQ-5Dindex and Oswestry; EQ-5Dvas and
Oswestry; days in bed and EQ-5Dindex; days in bed and
EQ-5Dvas; days in bed and Oswestry. Corresponding
correlation coefficients were 0.71; 0.74; 0.67; 0.55;
0.36; 0.4 (p  0.01). CONCLUSIONS: Results showed
that LBP leads to substantial loss in quality of life, impor-
tant direct medical costs, and substantial productivity
costs among active patients. Different health status mea-
sures correlated strongly to each other but the most im-
portant cost driver, i.e. days on sick leave did not show
any correlation with these.
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ADDRESSING PARADOXES IN ECONOMIC 
EVALUATIONS (EES). AN EXAMPLE USING 
MOTOR NEURON DISEASE (MND)
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BACKGROUND: MND results in progressive degenera-
tion of the motor neurons, with intellect remaining
largely unaffected. Average life expectancy from diagno-
sis to death is 2–5 years. Riluzole is the only treatment
which has been shown to extend life in MND, though its
cost-effectiveness has been questioned. In recent years,
there has been a large increase in the number of EEs.
Many have been criticised due to methodological defi-
ciencies. Using MND as an example, it is clear that EEs
can provide either valuable or misleading information in
a decision-making context. METHODS: Systematic search
for, and critical appraisal of, available EEs of riluzole
therapy for MND. RESULTS: The methodological qual-
ity of the six identified studies was variable. The study
with the greatest validity concluded that riluzole is a cost-
